Table II.
Selected studies of single-agent HD-MTX vs. MTX-based polychemotherapy with RTX.
| First author/s (year) | n | MTX dose, g/m2 | RTX dose, mg/m2 | Other drugs | ORR (CRR), %a | Median PFS, months | Median OS, months | Comments | (Ref.) |
|---|---|---|---|---|---|---|---|---|---|
| Single-agent HD-MTX | |||||||||
| Herrlinger et al (2002) | 37 | 8 | – | – | 34 (29) | 10 | 25 | Prospective | (11) |
| Batchelor et al (2003) | 25 | 8 | – | – | 74 (52) | 12 | >23 | Prospective | (10) |
| Combined HD-MTX and RTX | |||||||||
| Shah et al (2007) | 30 | 3.5 | 500 | Vincristine, procarbazine | 93 (78) | N/A; 57% estimated 2-year PFS rate | 40 (estimated) | Prospective Followed by WBRT (23.4 Gy if CR to induction vs. 45 Gy if less than CR attained); consolidation with IT cytarabine | (16) |
| Chamberlain and Johnston (2010) | 40 | 8 | 375 | – | 80 (60) | 21 | 29 (estimated) | Prospective | (14) |
| Fritsch et al (2011) | 28 | 3 | 375 | Procarbazine, lomustine | 82 (64) | 16 | 17.5 | Prospective; all patients ≥65 years | (18) |
| Birnbaum et al (2012) | 17 | 4 | 375 | Ifosfamide | 100 (59) | 18 | Not reached | Retrospective | (15) |
| Holdhoff et al (2014) | 27 | 8 | 375 | – | 89 (73) | 27 | Not reached | Retrospective | (24) |
| Present study | 12 | 8 | 375 | – | 91 (58) | 22 | Not reached | Retrospective |
a
Following induction with MTX and/or RTX ± additional drugs, but prior to administration of WBRT or consolidation treatment. CR, complete response; CR, CR rate; HD-MTX, high-dose methotrexate; IT, intrathecal; N/A, not available; OS, overall survival; ORR, overall response rate; PFS, progression-free survival; RTX, ritituximab; TMZ, temozolomide; WBRT, whole-brain radiotherapy.